Skip to content
Screener

Common Stock at other companies

PVL
Palvella TherapeuticsPVLA
$14K+27.3%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
2B0.0%
Celcuity logo
CelcuityCELC
95M0.0%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$21K+16.7%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
60M0.0%
Immunome logo
ImmunomeIMNM
$11K+22.2%

Other financials

Income statement

See full
Revenue$350.0K-48.3%
Operating income-$90.8M-18.2%
Net income-$83.7M-18.9%
EPS (diluted)-$0.410.0%

Balance sheet

See full
Cash & equivalents$121.2M+6.4%
Total debt$30.7M-10.3%
Total equity$890.0M+33.7%
Total assets$967.5M+32.7%

Cash flow

See full
Operating cash flow-$54.1M+2.1%
CapEx$1.0K
Free cash flow-$44.9M+22.5%

Valuation

See full
Market cap$4.3B+611%
Enterprise value$4.21B+702%
P/S415.9×+343×

Profitability

See full
Operating margin-2,999.4%-637pp
Net margin-2,763.6%-568pp
FCF margin-1,536%-429pp

Returns & leverage

See full
Return on equity-36.8%-6.3pp
Debt / equity0.0×
Current ratio18.3×-2.7×

Where this comes from

Reported directly by Relay Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The source filing: Relay Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:15 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338056
Line itemJune 30, 2026December 31, 2025
Commitments and contingencies (Note 9)
Stockholders’ equity:
Undesignated preferred stock, $0.001 par value, 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; no shares issued and outstanding as of June 30, 2026 and December 31, 2025
Common stock, $0.001 par value; 450,000,000 and 300,000,000 shares authorized as of June 30, 2026, and December 31, 2025, respectively; 218,531,200 and 173,868,949 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively211168
Additional paid-in capital3,063,1182,580,928
Accumulated other comprehensive (loss) gain(1,553)733
Accumulated deficit(2,171,767)(2,014,769)
Total stockholders’ equity890,009567,060

Item 1. Financial Statements.

FAQ

What is Relay Therapeutics, Inc.'s common stock?
Relay Therapeutics, Inc. (RLAY) reported common stock of $211K in Q2 2026.
How has Relay Therapeutics, Inc.'s common stock changed year-over-year?
Relay Therapeutics, Inc.'s common stock increased by 25.6% year-over-year, from $168K to $211K.
What is the long-term trend for Relay Therapeutics, Inc.'s common stock?
Over 5 years (2020 to 2025), Relay Therapeutics, Inc.'s common stock has grown at a 13.3% compound annual growth rate (CAGR), from $90K to $168K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Relay Therapeutics, Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude